Sunday, 14 August 2022


Seegene unveils '$12 PCR testing' initiative to help end COVID-19 pandemic

26 May 2022 | News

Includes asymptomatic testing at community-based facilities to prevent widespread transmissions

Image credit: shutterstock

Image credit: shutterstock

Seegene Inc., South Korea's leading molecular diagnostics (MDx) company, has unveiled a global initiative for preemptive and routine PCR testing to help individuals stay safe and healthy while living in the COVID-19 era.

Dr. Jong-Yoon Chun, CEO of Seegene, said the initiative is designed to help people safely return to normalcy and contribute to global efforts to terminate COVID-19 and prevent future outbreaks.

Seegene's initiative dubbed 'In-life PCR,' entails 1) asymptomatic testing for early virus detection 2) syndromic respiratory testing as anti-virus restrictions are eased and 3) boosting PCR test accessibility through affordable pricing.

Seegene will provide Allplex SARS-CoV-2 FluA/FluB/RSV Assay, which can simultaneously detect SARS-CoV-2 (via the N, RdRP and S gene), influenza A and B, and RSV (A/B). The WHO recommends the screening of at least two target genes for SARS-CoV-2. Seegene's assay identifies three to maintain detection accuracy if new COVID-19 variants emerge. The six-target assay also includes two internal controls for added accuracy.

The company will work with hospitals and labs so that a test can cost around $12 to boost accessibility and encourage routine testing. High multiplex technologies that build upon the company's 20+ years of expertise in molecular diagnostics have enabled Seegene to lower the barrier to access.

 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account